Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
NCT04845139Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in primary central nervous system lymphoma (PCNSL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Adverse events at 1 month. Status: unknown.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04845139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04845139.